These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

528 related items for PubMed ID: 12641624

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. [Recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma].
    Gómez Camarero P, Martínez Brocca MA, Rodríguez Rodríguez JR, Navarro González E, Tirado Hospital JL, González Duarte D, Vázquez Albertino R, Astorga Jimenez R.
    Rev Esp Med Nucl; 2003; 22(5):295-305. PubMed ID: 14534005
    [Abstract] [Full Text] [Related]

  • 43. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data.
    Vural GU, Akkas BE, Ercakmak N, Basu S, Alavi A.
    Clin Nucl Med; 2012 Oct; 37(10):953-9. PubMed ID: 22899202
    [Abstract] [Full Text] [Related]

  • 44. 18F-FDG-PET/CT in Patients Affected by Differentiated Thyroid Carcinoma with Positive Thyroglobulin Level and Negative 131I Whole Body Scan. It's Value Confirmed by a Bicentric Experience.
    Bertagna F, Albano D, Bosio G, Piccardo A, Dib B, Giubbini R.
    Curr Radiopharm; 2016 Oct; 9(3):228-234. PubMed ID: 27210819
    [Abstract] [Full Text] [Related]

  • 45. Quantitative reverse transcription-polymerase chain reaction of circulating thyroglobulin messenger ribonucleic acid for monitoring patients with thyroid carcinoma.
    Ringel MD, Balducci-Silano PL, Anderson JS, Spencer CA, Silverman J, Sparling YH, Francis GL, Burman KD, Wartofsky L, Ladenson PW, Levine MA, Tuttle RM.
    J Clin Endocrinol Metab; 1999 Nov; 84(11):4037-42. PubMed ID: 10566646
    [Abstract] [Full Text] [Related]

  • 46. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal.
    Elisei R, Schlumberger M, Driedger A, Reiners C, Kloos RT, Sherman SI, Haugen B, Corone C, Molinaro E, Grasso L, Leboulleux S, Rachinsky I, Luster M, Lassmann M, Busaidy NL, Wahl RL, Pacini F, Cho SY, Magner J, Pinchera A, Ladenson PW.
    J Clin Endocrinol Metab; 2009 Nov; 94(11):4171-9. PubMed ID: 19850694
    [Abstract] [Full Text] [Related]

  • 47. Prognostic value of thyroglobulin after thyroidectomy before ablative radioiodine therapy in thyroid cancer.
    Grünwald F, Menzel C, Fimmers R, Zamora PO, Biersack HJ.
    J Nucl Med; 1996 Dec; 37(12):1962-4. PubMed ID: 8970514
    [Abstract] [Full Text] [Related]

  • 48. Diagnostic 131-iodine whole-body scan may be avoided in thyroid cancer patients who have undetectable stimulated serum Tg levels after initial treatment.
    Pacini F, Capezzone M, Elisei R, Ceccarelli C, Taddei D, Pinchera A.
    J Clin Endocrinol Metab; 2002 Apr; 87(4):1499-501. PubMed ID: 11932271
    [Abstract] [Full Text] [Related]

  • 49. Thyroglobulin measurement before rhTSH-aided 131I ablation in detecting metastases from differentiated thyroid carcinoma.
    Giovanella L, Ceriani L, Suriano S, Ghelfo A, Maffioli M.
    Clin Endocrinol (Oxf); 2008 Oct; 69(4):659-63. PubMed ID: 18363882
    [Abstract] [Full Text] [Related]

  • 50. 99mTc-sestamibi and 131I whole-body scintigraphy and initial serum thyroglobulin in the management of differentiated thyroid carcinoma.
    Ng DC, Sundram FX, Sin AE.
    J Nucl Med; 2000 Apr; 41(4):631-5. PubMed ID: 10768563
    [Abstract] [Full Text] [Related]

  • 51. Management of low-risk patients with thyroid carcinoma and detectable thyroglobulin on T4 after thyroidectomy and ablation with iodine-131.
    Rosário PW, Borges MA, Costa GB, Rezende LL, Padrão EL, Barroso AL, Purisch S.
    Arq Bras Endocrinol Metabol; 2007 Feb; 51(1):99-103. PubMed ID: 17435862
    [Abstract] [Full Text] [Related]

  • 52. [Follow-up of high-risk patients with differentiated thyroid cancer without persistent disease after initial therapy].
    do Rosário PW, Borges MA, Alves MF, Purisch S, Padrão EL, Rezende LL, Barroso AL.
    Arq Bras Endocrinol Metabol; 2006 Oct; 50(5):909-13. PubMed ID: 17160215
    [Abstract] [Full Text] [Related]

  • 53. Relative value of thallium-201 and iodine-131 scans in the detection of recurrence or distant metastasis of well differentiated thyroid carcinoma.
    Lin JD, Kao PF, Weng HF, Lu WT, Huang MJ.
    Eur J Nucl Med; 1998 Jul; 25(7):695-700. PubMed ID: 9662590
    [Abstract] [Full Text] [Related]

  • 54. Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy.
    Torlontano M, Crocetti U, Augello G, D'Aloiso L, Bonfitto N, Varraso A, Dicembrino F, Modoni S, Frusciante V, Di Giorgio A, Bruno R, Filetti S, Trischitta V.
    J Clin Endocrinol Metab; 2006 Jan; 91(1):60-3. PubMed ID: 16219716
    [Abstract] [Full Text] [Related]

  • 55. Value of thyroglobulin to 131I uptake ratio in selection of initial therapy dose of 131I in patients with differentiated thyroid carcinoma.
    Zerva B, Koutsikos J, Palestidis C, Kounadi E, Gerali S.
    Q J Nucl Med Mol Imaging; 2006 Dec; 50(4):348-54. PubMed ID: 17043633
    [Abstract] [Full Text] [Related]

  • 56. Impact factors for the outcome of the first 131I radiotherapy in patients with papillary thyroid carcinoma after total thyroidectomy.
    Shangguan L, Fang S, Zhang P, Han S, Shen X, Geng Y, Luo D, Zhao C.
    Ann Nucl Med; 2019 Mar; 33(3):177-183. PubMed ID: 30515649
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Is empirical radioactive iodine therapy still a valid approach to patients with thyroid cancer and elevated thyroglobulin?
    Rosario PW, Mourão GF, dos Santos JB, Calsolari MR.
    Thyroid; 2014 Mar; 24(3):533-6. PubMed ID: 24067080
    [Abstract] [Full Text] [Related]

  • 59. Should 'low-risk' thyroid cancer patients with residual thyroglobulin be re-treated with iodine 131?
    Hindié E, Zanotti-Fregonara P, Duron F, Keller I, Bouchard P, Devaux JY.
    Clin Endocrinol (Oxf); 2007 Mar; 66(3):329-34. PubMed ID: 17302864
    [Abstract] [Full Text] [Related]

  • 60. Serum thyroglobulin and iodine-131 whole-body scan in the diagnosis and assessment of treatment for metastatic differentiated thyroid carcinoma.
    Lubin E, Mechlis-Frish S, Zatz S, Shimoni A, Segal K, Avraham A, Levy R, Feinmesser R.
    J Nucl Med; 1994 Feb; 35(2):257-62. PubMed ID: 8294995
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 27.